18F-FMAU PET追踪多西他赛诱导的前列腺肿瘤小鼠细胞增殖变化
这项探索性临床前研究在PC-3前列腺癌荷瘤小鼠中评估18F-FMAU PET定量测量化疗后细胞增殖变化的效果。多西他赛治疗组肿瘤生长受抑,但18F-FMAU肿瘤摄取从第0天3.09±0.60 %ID/g显著升至第22天5.32±0.37 %ID/g,对照组相对稳定。结论认为18F-FMAU摄取在多西他赛治疗下反而增加,机制待阐明。
要点
- 多西他赛抑制PC-3肿瘤生长,但18F-FMAU肿瘤摄取反而显著增高。
- 18F-FMAU PET可能反映治疗后的增殖 flare 效应,判读需谨慎。
- 临床前小鼠模型结果,尚不能直接外推至前列腺癌患者。
核心结论
- 18F-FMAU在植入的PC-3肿瘤中的摄取随多西他赛治疗而增加,尽管肿瘤生长受到抑制。
- 需进一步研究阐明这种表观flare效应的生物学机制及其与多西他赛疗效预测的关系。
研究设计与样本
- 探索性临床前研究,使用雄性无胸腺nu/nu小鼠右侧胁部接种PC-3细胞建立前列腺癌模型。
- 肿瘤直径达5 mm后,多西他赛组静脉注射24 mg/kg、每周两次,对照组静脉注射生理盐水。
- 监测肿瘤大小和体重,并在第0、11、18、22天注射18F-FMAU后2小时进行纵向PET扫描。
- 第22天PET扫描后进行生物分布研究。
关键影像表现/征象
- 多西他赛组18F-FMAU肿瘤摄取从第0天3.09±0.60 %ID/g显著增至第22天5.32±0.37 %ID/g。
- 对照组18F-FMAU肿瘤摄取第0天2.37±0.51 %ID/g,第22天1.83±0.22 %ID/g,相对稳定。
- 多西他赛组肿瘤/肌肉摄取比从第0天2.63±0.20增至第22天5.91±1.1。
- 第22天多西他赛组与对照组肿瘤/肌肉摄取比无统计学显著性差异。
- 第22天多西他赛组肿瘤/肝脏摄取比4.29±0.09,对照组3.83±0.59,两者相似。
临床应用与阅片要点
- 18F-FMAU PET可用于临床前评估肿瘤细胞增殖变化,但治疗后的摄取增高不一定代表治疗失败。
- 判读多西他赛治疗后的18F-FMAU PET时需警惕flare效应,避免将摄取增高误判为进展。
- 肿瘤/肌肉和肿瘤/肝脏摄取比可作为半定量参考,但两组间第22天无显著差异。
局限性
- 本研究为探索性临床前小鼠模型研究,样本量小,结果不能直接外推至临床患者。
- 原文未阐明18F-FMAU摄取增加的生物学机制,需进一步研究。
- 原文未报告统计学P值和置信区间等详细统计结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this exploratory preclinical study was to evaluate the efficacy of 18F-FMAU PET in quantitatively measuring cellular proliferation changes in response to a chemotherapeutic agent in experimental prostate cancer models.
METHODS AND MATERIALS: Docetaxel (DTX) ‒ a standard therapy agent in castrate-resistant metastatic prostate cancer was used as the chemotherapy drug. Athymic male nu/nu mice were inoculated with PC-3 cells in the right flank. After the tumor diameter reached 5 mm, DTX (24 mg/kg) was injected intravenously twice a week, whereas the control group was intravenously administered with saline. The tumor size and body weight were monitored, and longitudinal PET scans were acquired with 18F-FMAU to evaluate tumor cellular proliferation. 18F-FMAU PET scans were performed at 2 hours post-injection of 18F-FMAU on days 0, 11, 18, and 22. Biodistribution studies were carried out after the PET scan on day 22.
RESULTS: Consecutive administrations of DTX were effective in inhibiting PC-3 tumor growth compared to the control group. For PET imaging, PC-3 tumor uptake of 18F-FMAU in the DTX group was increased significantly from 3.09 ± 0.60 %ID/g (day 0) to 5.32 ± 0.37 %ID/g (day 22), whereas the 18F-FMAU tumor update in the control group remained relatively stable on day 0 (2.37 ± 0.51 %ID/g) vs. day 22 (1.83 ± 0.22 %ID/g). The tumor-to-muscle uptake ratio of 18F-FMAU was increased from 2.63 ± 0.20 (day 0) to 5.91 ± 1.1 (day 22) in the DTX group. On day 22, no statistical significance was observed in the tumor-to-muscle uptake ratio of 18F-FMAU in the DTX group vs. the control group. The tumor-to-liver uptake ratio of 18F-FMAU was also similar on day 22 in the DTX group (4.29 ± 0.09) vs. the control group (3.83 ± 0.59).
CONCLUSION: 18F-FMAU uptake in implanted PC-3 tumors increases with DTX despite inhibiting tumor growth. Further investigation is needed to decipher the underlying biological mechanism of this apparent flare effect and its relation to the predictability of tumor response to DTX.
引用
- Jadvar, Park, Vorobyova, et al. Tracking Docetaxel-Induced Cellular Proliferation Changes in Prostate Tumor-Bearing Mice with 18F-FMAU PET. Acad Radiol. 2022. PMID: 36184379. doi:10.1016/j.acra.2022.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。